HOXC8 and non-small cell lung carcinoma: Taken together, these data indicated that HOXC8 expression could amplify the chemoresistance NSCLC to cisplatin-based chemotherapy and down-regulation of HOXC8 effectively improved the sensitivity of NSCLS to cisplatin treatment.